Clinical Trials Logo

Acute Chest Syndrome clinical trials

View clinical trials related to Acute Chest Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05640271 Recruiting - Sickle Cell Disease Clinical Trials

Tocilizumab for Acute Chest Syndrome

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19. Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigators are hopeful that this will be an effective strategy. The investigators will be looking at how a low dose of tocilizumab affects oxygen status, clinical outcomes, and laboratory markers in patients admitted to the hospital with acute chest syndrome.

NCT ID: NCT03498105 Recruiting - Clinical trials for Acute Chest Syndrome

Utility of the Cardiac Electrical BiomarkerDisease

VECTRA
Start date: May 22, 2017
Phase:
Study type: Observational

This project is aiming to identify the diagnostic utility CEB (Cardiac Electrical Biomarker) in patients who are undergoing cardiac investigations.

NCT ID: NCT03032055 Recruiting - Clinical trials for Acute Chest Syndrome

Validation of a Predictive Score of Acute Chest Syndrome

Presev2
Start date: January 1, 2016
Phase:
Study type: Observational

Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS). The PRESEV score could help the physicians to better manage VOC and could be used for future therapeutic trials. This predictive score of secondary ACS has to be validated in a multicenter international study.